UC San Diego
SCHOOL OF MEDICINE
Shiley-Marcos Alzheimer's Disease Research Center

Altman Clinical and Translational Research Institute Building
9500 Gilman Drive, MC 0949, 4th Floor, La Jolla CA 92093-0949
Telephone: 858-822-4800 (ADRC main)
clinicaltrialsADRC@health.ucsd.edu

Studies	BDNF Gene Therapy	Janssen JNJ-63733657ALZ2002	VIVA-MIND	Alzheon APOLLE4 ALZ-801	AVANIR ASPECT AVP-786	Alector AL001-3
Required Diagnosis	MCI or probable mild **Alzheimer's Disease**	Prodromal/Early **Alzheimer's Disease**	MCI due to Alzheimer's Disease, or mild probable **Alzheimer's Disease**	MCI or Mild Dementia due to **Alzheimer's Disease**, and **APOE4/4 genotype**	Probable **Alzheimer's Disease & Clinically significant, moderate-to-severe agitation**	**Frontotemporal Dementia** and **heterozygous loss-of-function progranulin gene (GRN) mutations**
Phase	1	2	2A/2B	3	3	3
Route of Drug Administration	Neurosurgery	Infusion	Oral tablet	Oral tablet	Oral tablet	Infusion
Age	Minimum 50	55 - 80 (inclusive)	50 – 89 (inclusive)	50 - 80 (inclusive)	50 - 90 (inclusive)	25 - 85 (inclusive)
Length	Overall study length 2 years with visits in San Diego, with surgical procedure in Ohio	90 days screening + treatment up to 4.5 yrs + safety follow-up 90 days after last dose	Min. of 24 wks for phase 2A. Phase 2B is planned to follow	Up to 11 wks screening + 78 wks of treatment + 4 wks (follow-up)	28 days screening + 12 wks of treatment + 30-day post-dose follow-up	96 wks of treatment + optional 96 wks of Open Label Extension + 10 wks (follow-up)
Lumbar Puncture	3 times	Optional - 4 LPs (1 at screening and 3 during treatment)	3 times	No	No	Optional every 48 wks (1 at screening and 2 during treatment; 2 during optional OLE)
MRI	Required	Required	Required	Required for most	No	Required
Amyloid PET	Required	No	No	No	No	No
Tau PET	No	Required	No	No	No	No
Compensation	Yes	Yes	Yes	Yes	Yes	Yes
Read more on clinicaltrials.gov	Identifier: NCT05040217	Identifier: NCT04619420	Identifier: NCT03919162	Identifier: NCT04770220	Identifier: NCT0339520	Identifier: NCT04374136

Required for all studies: Must have a study partner; No recent changes in AD medications or doses; Must be willing to undergo an MRI; No history of medical conditions other than the required diagnosis (e.g., AD, FTD) that could account for cognitive deficits.

FOR ALL STUDIES, PLEASE CONTACT clinicaltrialsADRC@health.ucsd.edu for more details

Information as of 11/01/2021